Compare BridgeBio Pharma Inc (BBIO) vs Invesco Galaxy Bitcoin ETF (BTCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Invesco Galaxy Bitcoin ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Invesco Galaxy Bitcoin ETF trades at $63.04. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, Invesco Galaxy Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | BTCO | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Crypto-linked |
52-Week High | $90.17 | $125.14 |
52-Week Low | $47.29 | $58.40 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
BTCO stock trades at $64.60, up 0.86% today amid mixed technical signals. The overall technical picture shows bearish momentum with key support at $63 and resistance at $65. Financial ratios remain unavailable in current data, requiring fundamental verification through SEC filings.
Investment outlook hinges on forthcoming financial disclosures to assess valuation. Key risks include market volatility and competitive pressures. The stock's near-term direction will likely be driven by earnings results and institutional positioning updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Invesco Galaxy Bitcoin ETF
BTCO is a spot Bitcoin ETF that tracks the price of Bitcoin directly. It offers investors a regulated and convenient way to gain exposure to the digital currency through a traditional brokerage account without holding the asset.
Read more on BTCO →
